secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001104659-23-027442
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics regains Nasdaq minimum bid price compliance
--------------------------------------------------------------

- Received Nasdaq deficiency letter on Sept 12, 2022 for bid price below $1.00.
- Regained compliance on March 1, 2023 after 10 consecutive trading days above $1.00 (Feb 14-28).
- CEO Oren Gilad cited recent financing and progress on clinical asset ATRN-119 and pre-clinical ATRN-W1051.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923027442/0001104659-23-027442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923027442/tm238260d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-027442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer